HR Execs on the Move

Boyd Industries Inc

www.boydindustries.com

 
Boyd Industries Inc is a Clearwater, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Addiction Prevention

Addiction Prevention is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Horizon Treatment Services

Horizon Services provides a safe and effective place for individuals to receive addiction treatment and begin their journey toward sustainable, fulfilling recovery. Our Mission is to cultivate or restore a sense of hope, self-awareness and community to people impacted by substance use and mental health challenges by providing effective trauma informed prevention, treatment, and recovery services.

VTS Medical Systems

VTS Medical Systems is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spherix Inc

Spherix Incorporated was launched in 1967 as a scientific research company.  Spherix is committed to advancing innovation by active participation in the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation.

Foghorn Therapeutics

More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.